Surgery must be recognised as a treatment option for Type 2 diabetes
First-ever Type 2 diabetes surgery clinical guidelines from leading international diabetes organisations
A leading group of international diabetes organisations is calling for obesity surgery to be recognised as a standard treatment option for Type 2 diabetes.
In a joint statement, published today (Tuesday 24 May) in the June 2016 edition of the journal Diabetes Care, the group state that obesity surgery, which was originally designed to induce weight loss, should be included among the current treatment options for certain categories of people with Type 2 diabetes.
The new guidelines state that surgery should be recommended to treat people with Type 2 diabetes who have a BMI of 40 and over, regardless of their blood glucose control, as well as people with a BMI of 30 and over whose blood glucose levels are inadequately controlled by lifestyle changes and blood glucose lowering medication. It is also recommended that the BMI thresholds in Asian people with Type 2 diabetes should be lower as they develop Type 2 diabetes at a lower BMI compared to other populations.
The guidelines are based on a wide body of evidence, including 11 randomised trials, showing that in most cases surgery can lead to reductions in blood glucose levels below the Type 2 diabetes diagnosis threshold or a substantial improvement in blood glucose levels leading to a reduction in medication. Economic studies also show that the treatment can be cost effective.
The new guidelines emerged from the Second Diabetes Surgery Summit (DSS-II), an international consensus conference held September 28–30, 2015, in London, and jointly organised with Diabetes UK, the American Diabetes Association, International Diabetes Federation, Chinese Diabetes Society, and Diabetes India. The goal of the Summit was to develop global guidelines to inform clinicians and policy makers about benefits and limitations of Type 2 diabetes surgery.
It is essential that people with diabetes have access to effective treatments and are supported to manage their condition well. This is because poorly controlled diabetes can lead to serious complications such as blindness, amputations and stroke. As well as the human cost, these complications are also extremely costly to the NHS. The NHS spends 10 billion every year managing diabetes, and 80 per cent of this cost is spent on complications.
Diabetes UK is calling for the new guidelines to be fully incorporated into the existing guidelines for treating Type 2 diabetes so that everyone who fits the surgery criteria is assessed for treatment. While NICE updated its obesity surgery criteria for people with Type 2 diabetes in 2014, the specific recommendations in these guidelines do not appear in full in its Type 2 diabetes treatment guidelines, which was published last year.
Simon O’Neill, Director of Health Intelligence and Professional Liaison at Diabetes UK, said: “We strongly support the call for obesity surgery to be fully recognised as an active treatment option for Type 2 diabetes alongside established forms of Type 2 diabetes treatments, such as lifestyle changes, and blood glucose lowering medications. This is because there is a wide body of evidence that shows surgery is an effective treatment option for Type 2 diabetes and can be cost effective for the NHS.”
“However, many people who stand to benefit from this potentially lifesaving treatment are missing out due to needless barriers to obesity surgery services. Even people who meet the criteria for the surgery are being made to wait too long, even though we know that people with Type 2 diabetes benefit most from the surgery if it is carried out closer to the time they were diagnosed.”
“This is why the National Institute for Health and Care Excellence (NICE) must make it explicit in its Type 2 diabetes guidelines that those with Type 2 diabetes who meet the recommended criteria for obesity surgery should be referred for early assessment for surgery and supported to make an informed choice. These recommendations are currently stated in the NICE obesity guidelines, but are not fully incorporated in current NICE Type 2 diabetes guidelines.”
“It is also essential that healthcare professionals are aware of the potential benefits of surgery for their patients with Type 2 diabetes and commissioners ensure they have measures in place to support greater access to obesity surgery services.”
“Type 2 diabetes is a serious health condition that can lead to debilitating and life threatening complications so it is essential that all effective treatment options for people with Type 2 diabetes are made available.”
“The UK is in the midst of an epidemic of diabetes, like many other countries around the world, and prevention of Type 2 diabetes remains crucial”; said Professor Francesco Rubino, Chair of Metabolic and Bariatric Surgery at King’s College London, Consultant surgeon at King’s College Hospital and first author on the guidelines report. “Prevention, however, is obviously no longer an option for the many patients diagnosed with Type 2 diabetes. These patients should have access to all effective treatment options; for some, surgery may be the best choice” he added.
Obesity surgery involves the removal of part of the stomach or reroutes the small intestine. The surgery is similarly safe compared to commonly performed operations such as gallbladder surgery, but there is still a risk of complications and long term nutritional deficiencies, which require lifelong vitamin/nutritional supplementation and rigorous long-term follow up by specialist teams.
Being overweight is a significant risk factor for Type 2 diabetes, but there are other risk factors that play an important part, such as age, family history, and ethnicity.
The full articles, joint statement and commentary will be published online at http://care.diabetesjournals.org/content/current on May 24, 2016, 15.00.